Janvilisri Tavan, Shahi Sanjay, Venter Henrietta, Balakrishnan Lekshmy, van Veen Hendrik W
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.
Biochem J. 2005 Jan 15;385(Pt 2):419-26. doi: 10.1042/BJ20040791.
The human BCRP (breast cancer resistance protein, also known as ABCG2) is an ABC (ATP-binding cassette) transporter that extrudes various anticancer drugs from cells, causing multidrug resistance. To study the molecular determinants of drug specificity of BCRP in more detail, we have expressed wild-type BCRP (BCRP-R) and the drug-selected cancer cell line-associated R482G (Arg482-->Gly) mutant BCRP (BCRP-G) in Lactococcus lactis. Drug resistance and the rate of drug efflux in BCRP-expressing cells were proportional to the expression level of the protein and affected by the R482G mutation, pointing to a direct role of BCRP in drug transport in L. lactis. In agreement with observations in mammalian cells, the BCRP-R-mediated transport of the cationic substrates rhodamine 123 and tetramethylrosamine was significantly decreased compared with the activity of BCRP-G. In addition, BCRP-R showed an enhanced interaction with the anionic anticancer drug methotrexate when compared with BCRP-G, suggesting that structure/substrate specificity relationships in BCRP, as observed in eukaryotic expression systems, are maintained in prokaryotic L. lactis. Interestingly, BCRP-R exhibited a previously unestablished ability to transport antibiotics, unconjugated sterols and primary bile acids in L. lactis, for which the R482G mutation was not critical. Since Arg482 is predicted to be present in the intracellular domain of BCRP, close to transmembrane segment 3, our results point to a role of this residue in electrostatic interactions with charged substrates including rhodamine 123 and methotrexate. Since unconjugated sterols are neutral molecules and bile acids and many antibiotics are engaged in protonation/deprotonation equilibria at physiological pH, our observations may point either to a lack of interaction between Arg482 and neutral or neutralized moieties in these substrates during transport or to the interaction of these substrates with regions in BCRP not including Arg482.
人类乳腺癌耐药蛋白(BCRP,也称为ABCG2)是一种ABC(ATP结合盒)转运蛋白,可将多种抗癌药物排出细胞,导致多药耐药。为了更详细地研究BCRP药物特异性的分子决定因素,我们在乳酸乳球菌中表达了野生型BCRP(BCRP-R)和与药物选择的癌细胞系相关的R482G(Arg482→Gly)突变型BCRP(BCRP-G)。表达BCRP的细胞中的耐药性和药物外排速率与蛋白质的表达水平成正比,并受R482G突变的影响,这表明BCRP在乳酸乳球菌的药物转运中起直接作用。与在哺乳动物细胞中的观察结果一致,与BCRP-G的活性相比,阳离子底物罗丹明123和四甲基罗丹明的BCRP-R介导的转运显著降低。此外,与BCRP-G相比,BCRP-R与阴离子抗癌药物甲氨蝶呤的相互作用增强,这表明在真核表达系统中观察到的BCRP中的结构/底物特异性关系在原核乳酸乳球菌中得以维持。有趣的是,BCRP-R在乳酸乳球菌中表现出一种以前未确定的转运抗生素、未结合的固醇和初级胆汁酸的能力,而R482G突变对此并不关键。由于预测Arg482存在于BCRP的细胞内结构域中,靠近跨膜片段3,我们的结果表明该残基在与包括罗丹明123和甲氨蝶呤在内的带电底物的静电相互作用中起作用。由于未结合的固醇是中性分子,胆汁酸和许多抗生素在生理pH下参与质子化/去质子化平衡,我们的观察结果可能表明在转运过程中Arg482与这些底物中的中性或中和部分之间缺乏相互作用,或者这些底物与BCRP中不包括Arg482的区域相互作用。